Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exagen (XGN) Consolidated Net Income (2018 - 2025)

Historic Consolidated Net Income for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to -$7.1 million.

  • Exagen's Consolidated Net Income fell 4095.07% to -$7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.0 million, marking a year-over-year decrease of 1269.68%. This contributed to the annual value of -$15.1 million for FY2024, which is 3619.4% up from last year.
  • Latest data reveals that Exagen reported Consolidated Net Income of -$7.1 million as of Q3 2025, which was down 4095.07% from -$4.4 million recorded in Q2 2025.
  • In the past 5 years, Exagen's Consolidated Net Income ranged from a high of -$3.0 million in Q2 2024 and a low of -$15.1 million during Q4 2022
  • For the 5-year period, Exagen's Consolidated Net Income averaged around -$6.8 million, with its median value being -$6.2 million (2021).
  • In the last 5 years, Exagen's Consolidated Net Income crashed by 12886.12% in 2022 and then soared by 6582.82% in 2023.
  • Over the past 5 years, Exagen's Consolidated Net Income (Quarter) stood at -$7.1 million in 2021, then crashed by 114.33% to -$15.1 million in 2022, then skyrocketed by 63.35% to -$5.5 million in 2023, then soared by 32.11% to -$3.8 million in 2024, then tumbled by 88.43% to -$7.1 million in 2025.
  • Its last three reported values are -$7.1 million in Q3 2025, -$4.4 million for Q2 2025, and -$3.8 million during Q1 2025.